Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy (NCT07220785) | Clinical Trial Compass
RecruitingPhase 3
Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy
United States28 participantsStarted 2026-03-13
Plain-language summary
This study is researching a new drug called mibavademab (called "study drug"). The study involves participants with a condition called Generalized Lipodystrophy (GLD). The aim of the study is to see how well mibavademab works and what side effects it has. Researchers will also look at how much mibavademab is in the body at different times.
This is a 2-part study: Part A is an efficacy study in pediatric and adult participants, Part B is a safety and pharmacokinetic study in pediatric participants.
The study is researching several other questions, including:
* How mibavademab affects the amount of sugar in the blood
* How mibavademab affects the amount of fat (triglycerides) in the blood
* How mibavademab affects the amount of fat that has built up in the liver
* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Who can participate
Age range2 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Participants ≥2 years of age at screening
✓. At least one of the below criteria are fulfilled during screening (measurements can be repeated once during screening period)
✓. Weight ≥15 kg at screening
✓. Willing and able to provide, or have the treating physician provide, values of HbA1c and fasting TG from at least 6 months prior to screening, as described in the protocol
✓. Participants \<12 years of age at screening
✓. Weighing ≥7 kg at screening
✓. No metabolic criteria for study entry is required, as described in the protocol
Exclusion criteria
✕. Has a current diagnosis of familial or acquired partial lipodystrophy or autoimmune (Type 1) diabetes mellitus
✕. Any malignancy, eg, lymphoma, within the past 1 year, prior to screening visit, as described in the protocol
What they're measuring
1
Change in Hemoglobin A1c (HbA1c)
Timeframe: Through 36 weeks of exposure to mibavademab
2
Percent change in fasting Triglycerides (TG)
Timeframe: Through 36 weeks of exposure to mibavademab
3
Occurrence of Treatment Emergent Adverse Events (TEAEs)
. eGFR of \<30 mL/min/1.73 m2 based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine or Schwartz equation, as applicable, at screening. Assessment can be repeated once
✕. History of heart failure hospitalization, diagnosis of a myocardial infarction, stroke, clinically significant arrhythmia, as described in the protocol
✕. Treatment with over-the-counter or prescription medications with the intention of weight loss within 3 months prior to the screening visit
✕. Treatment with metreleptin within 3 months of the screening visit
✕. Addition or discontinuation of prescription medications or over-the-counter supplements for diabetes and/or dyslipidemia within 3 months prior to the start of the screening period, or changes in the use of these medications, as described in the protocol
✕. Significant changes to lifestyle and diet, as described in the protocol